Australia  

New minimally-invasive treatment for 'frozen shoulder' improves patients' pain, function

Video Credit: ANI - Duration: 01:21s - Published
New minimally-invasive treatment for 'frozen shoulder' improves patients' pain, function

New minimally-invasive treatment for 'frozen shoulder' improves patients' pain, function

Scientists have developed a new nonsurgical treatment that decreases erranta blood flow in the shoulder to quickly reduce pain and improve function in patients with adhesive capsulitis, also known as "frozen shoulder," as per a recent research abstract.

The research abstract was presented during a virtual session of the Society of Interventional Radiology's 2020 Annual Scientific Meeting.

Frozen shoulder gradually causes significant pain and stiffness of the shoulder joint in an estimated 200,000 people in the U.S. each year.

The symptoms are often treated with physical therapy or pain medications until they resolve within one to three years.The research was conducted as a collaboration between interventional radiology and orthopaedic surgery to build on international studies of the procedure by adapting the treatment design and embolic agent to be more durable.

The team plans to expand the study to additional patients in 2020.

FDA-approved Investigational Device Exemption clinical trial on arterial embolization of the shoulder (AES), interventional radiologists inserted a catheter through a pinhole-sized incision in patients' wrists that was used to feed microsphere particles into as many as six arteries in the shoulder to reduce inflammation.

The treatment was conducted on an outpatient basis and took approximately one hour.

Each patient's pain, disability, and blood flow in the shoulder were measured before and after the treatment using three scales, in addition to MRI imaging to visualize the shoulder joint.The treatment was successfully completed in 16 patients whose symptoms had not responded to conservative treatment over 30 days.

The authors note that this treatment is still investigational and that conservative therapies should still be considered first.

Additionally, there are several important limitations of the research, including small sample size and lack of control arm.

0
shares
ShareTweetSavePostSend
 

💡 One News Page Knowledge: Other News Mentions

Interventional radiology Interventional radiology medical specialty which provides minimally invasive image-guided diagnosis and treatment of disease


Investigational device exemption Investigational device exemption


Food and Drug Administration Food and Drug Administration Agency of the United States Department of Health and Human Services

Too soon to say if RNC will be safe -U.S. official [Video]

Too soon to say if RNC will be safe -U.S. official

Stephen Hahn, the Food and Drug Administration commissioner, said on Sunday it was "too early to tell" if it would be safe for people to attend August's Republican National Convention in Jacksonville, Florida. This report produced by Chris Dignam.

Credit: Reuters Studio    Duration: 01:43Published
FDA Commissioner Won't Confirm Or Deny Trump's Unfounded COVID-19 Claim [Video]

FDA Commissioner Won't Confirm Or Deny Trump's Unfounded COVID-19 Claim

The commissioner of the US Food and Drug Administration on Sunday didn't defend a claim recently made by President Donald Trump. But according to CNN, he didn't support it, either. Dr. Stephen Hahn is a member of the White House coronavirus task force. At a White House Independence Day event on Saturday, Trump made an unfounded claim that 99% of coronavirus cases are 'totally harmless.' In a CNN interview with Dana Bash on Sunday, Dr.

Credit: Wochit News    Duration: 00:45Published
Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment [Video]

Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment

Gilead is the pharmaceutical company behind a drug that’s been approved for COVID emergencies. The FDA officially announced the medicine could be used in treating COVID-19 patients. Gilead has now announced the drug will cost $3,120 per typical treatment course for insured individuals. Research has indicated the drug could cut the recovery time for hospitalized COVID-19 patients. It could shorten satsy by several days, reports Gizmodo.

Credit: Wochit News    Duration: 00:35Published
Former FDA head says 'exponential' rise in COVID-19 possible [Video]

Former FDA head says 'exponential' rise in COVID-19 possible

Former Food and Drug Administration Commissioner Scott Gottlieb on Sunday warned that some U.S. states, including Texas, Florida and Arizona, could start to see an 'exponential' rise in COVID-19 cases this coming week. This report produced by Yahaira Jacquez.

Credit: Reuters - Politics    Duration: 01:40Published

You Might Like

Related news from verified sources

Orthocell completes recruitment for shoulder tendon study with Johnson & Johnson subsidiary

Orthocell Ltd (ASX:OCC) has completed the recruitment for its Ortho-ATI® shoulder tendon study in...
Proactive Investors - Published


Tweets about this


Related videos from verified sources

Mesa lab testing COVID-19 antibody treatment [Video]

Mesa lab testing COVID-19 antibody treatment

New trial seeks to find out if antibody infusions could help patients.

Credit: ABC15 Arizona     Duration: 02:23Published
Researchers develop eyedrops that prevent vision loss after retinal vein occlusion [Video]

Researchers develop eyedrops that prevent vision loss after retinal vein occlusion

Retinal vein occlusion which is a major cause of blindness for millions of adults worldwide can be prevented with a new eye drops solution developed by a team of researchers. A study, in mice, suggests..

Credit: ANI     Duration: 01:11Published
Patanjali claims 45 COVID-19 patients recovered in week after taking its medicine [Video]

Patanjali claims 45 COVID-19 patients recovered in week after taking its medicine

Patanjali claimed that COVID-19 patient group that received its medicines showed 69% recovery in 3 days and 100% recovery in 7 days of treatment. While addressing a press conference in Haridwar on July..

Credit: ANI     Duration: 01:30Published